ArticleCancer research2021
Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Phylogeography of Bone Metastasis: Clonal Evolution, Skeletal Niche Adaptation, and Clinical Implications.International journal of molecular sciences · 2026Review
- Cutting-edge advances in endocrine therapy for breast cancer (Review).Oncology letters · 2026Review
- ROS-Fueled Allies: STAT3, PKM2, and HIF-1α Influencing Energy Metabolism in Hormone-Independent Cancers.International journal of molecular sciences · 2026Article
- Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types.Experimental hematology & oncology · 2026Review
- Article
- Screening of PANoptosis regulator-associated long noncoding RNAs and construction of a survival prognostic model in cutaneous melanoma.Translational cancer research · 2025Article
- Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The GPR30 Receptor Is Involved in IL-6-Induced Metastatic Properties of MCF-7 Luminal Breast Cancer Cells.International journal of molecular sciences · 2024Article
- The reprotoxic adverse side effects of neurogenic and neuroprotective drugs: current use of human organoid modeling as a potential alternative to preclinical models.Frontiers in pharmacology · 2024Review
- Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions.Cell & bioscience · 2023Review
- Breast cancer organoids and their applications for precision cancer immunotherapy.World journal of surgical oncology · 2023Review
- Urological cancer organoids, patients' avatars for precision medicine: past, present and future.Cell & bioscience · 2022Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Eugen DhimoleaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. constantine_mitsiades@dfci.harvard.edu eugen_dhimolea@dfci.harvard.edu.
Ricardo de Matos SimoesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-1700-5276
Dhvanir KansaraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Xiang WengDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shruti SharmaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pallavi AwateDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zhiyi LiuDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts.ORCID https://orcid.org/0000-0002-8122-8474
Dong GaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.
Nicholas MitsiadesBaylor College of Medicine, Houston, Texas.
Joseph H SchwabHarvard Medical School, Boston, Massachusetts.
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.ORCID https://orcid.org/0000-0002-0171-3884
Rinath JeselsohnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0001-7996-7529
Aedín C CulhaneDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute & Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-1395-9734
Myles BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Irene GeorgakoudiDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts.ORCID https://orcid.org/0000-0002-0049-6697
Constantine S MitsiadesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. constantine_mitsiades@dfci.harvard.edu eugen_dhimolea@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBroad Institute · USHarvard University · USMemorial Sloan Kettering Cancer Center · USTufts University · USBaylor College of Medicine · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0MTHE RNA HELICASE EIF4A IS A THERAPEUTIC VULNERABILITY IN TRIPLE-NEGATIVE BREAST CANCERU54CA233223 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MITSIADES, NICHOLAS · 2018 to 2022
$7.0MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MPatient-Derived Models of Prostate Cancer for Personalized MedicineU01CA224044 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, YU, FUTREAL, PHILLIP ANDREW · 2019 to 2023
$5.1MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MForegut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric Cancer RiskR01CA204113 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHEN, YU, PEI, ZHIHENG · 2016 to 2020
$3.8MOrchestra: A high performance biomedical supercomputing collaborativeS10RR028832 · NCRR · HARVARD MEDICAL SCHOOL · PI DANUSER, GAUDENZ · 2010 to 2010
$3.7MUnderstanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA204113NCI NIH HHS R01 CA208100NCI NIH HHS U01 CA224044NCI NIH HHS U54 CA224079NCI NIH HHS U54 CA233223NCRR NIH HHS S10 RR028832
Abstract
Although hormonal therapy (HT) inhibits the growth of hormone receptor-positive (HR
Indexed as
Drug Resistance, NeoplasmAnimalsAntineoplastic Agents, HormonalApoptosisBiomarkers, TumorBone NeoplasmsBreast NeoplasmsCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeProstatic NeoplasmsReceptors, EstrogenAntineoplastic Agents, HormonalBiomarkers, TumorReceptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.